4.5 Article

Anti-leishmanial activity of disubstituted purines and related pyrazolo[4,3-d]pyrimidines

Journal

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
Volume 21, Issue 14, Pages 4233-4237

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmcl.2011.05.076

Keywords

Leishmania; Cyclin-dependent kinase; Inhibitor; Therapy

Funding

  1. Czech Science Foundation [204/08/0511, 301/08/1649]
  2. Ministry of Education, Youth and Sports of the Czech Republic [MSM 6198959216]
  3. European Commission [LSHB-CT-2004-503467]
  4. Wellcome Trust
  5. Biotechnology and Biological Sciences Research Council
  6. MRC [G0400028] Funding Source: UKRI
  7. Medical Research Council [G0400028] Funding Source: researchfish

Ask authors/readers for more resources

We report here results of screening directed to finding new anti-leishmanial drugs among 2,6-disubstituted purines and corresponding 3,7-disubstituted pyrazolo[4,3-d]pyrimidines. These compounds have previously been shown to moderately inhibit human cyclin-dependent kinases. Since some compounds reduced viability of axenic amastigotes of Leishmania donovani, we screened them for interaction with recombinant leishmanial cdc-2 related protein kinase (CRK3/CYC6), an important cell cycle regulator of the parasitic protozoan. Eighteen pairs of corresponding isomers were tested for viability of amastigotes and for inhibition of CRK3/CYC6 kinase activity. Some compounds (9A, 12A and 13A) show activity against amastigotes with EC(50) in a range 1.5-12.4 mu M. Structure-activity relationships for the tested compounds are discussed and related to the lipophilicity of the compounds. (C) 2011 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available